Chad A Bousman1,2,3, Katarina Arandjelovic4, Serafino G Mancuso5, Harris A Eyre4,5,6,7, Boadie W Dunlop8. 1. Departments of Medical Genetics, Psychiatry, & Physiology & Pharmacology, University of Calgary, Calgary, Alberta T2N 4N1, Canada. 2. Alberta Children's Hospital Research Institute, Calgary, Alberta T2N 1N4, Canada. 3. Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada. 4. IMPACT SRC, School of Medicine, Deakin University, Geelong, Victoria, 3220, Australia. 5. Department of Psychiatry, University of Melbourne, Melbourne, Victoria, 3220, Australia. 6. Innovation Institute, Texas Medical Center, Houston, TX 77030, USA. 7. CNSDose LLC, Westlake Village, CA 91359, USA. 8. Department of Psychiatry & Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.
Abstract
AIM: To conducted a systematic review and meta-analysis of prospective, randomized controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools (DSTs) relevant to depressive symptom remission in major depressive disorder (MDD). PATIENTS & METHODS: Random-effects meta-analysis was performed on RCTs that examined the effect of DSTs on remission rates in MDD. RCT quality was assessed using the Cochrane Collaboration Criteria. RESULTS & CONCLUSION: A total of 1737 eligible subjects from five RCTs were examined. Individuals receiving pharmacogenetic-guided DST therapy (n = 887) were 1.71 (95% CI: 1.17-2.48; p = 0.005) times more likely to achieve symptom remission relative to individuals who received treatment as usual (n = 850). Pharmacogenetic-guided DSTs might improve symptom remission among those with MDD.
AIM: To conducted a systematic review and meta-analysis of prospective, randomized controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools (DSTs) relevant to depressive symptom remission in major depressive disorder (MDD). PATIENTS & METHODS: Random-effects meta-analysis was performed on RCTs that examined the effect of DSTs on remission rates in MDD. RCT quality was assessed using the Cochrane Collaboration Criteria. RESULTS & CONCLUSION: A total of 1737 eligible subjects from five RCTs were examined. Individuals receiving pharmacogenetic-guided DST therapy (n = 887) were 1.71 (95% CI: 1.17-2.48; p = 0.005) times more likely to achieve symptom remission relative to individuals who received treatment as usual (n = 850). Pharmacogenetic-guided DSTs might improve symptom remission among those with MDD.
Authors: Laura M Hack; Gabriel R Fries; Harris A Eyre; Chad A Bousman; Ajeet B Singh; Joao Quevedo; Vineeth P John; Bernhard T Baune; Boadie W Dunlop Journal: J Affect Disord Date: 2019-02-06 Impact factor: 4.839
Authors: Abdullah Al Maruf; Mikayla Fan; Paul D Arnold; Daniel J Müller; Katherine J Aitchison; Chad A Bousman Journal: Can J Psychiatry Date: 2020-02-17 Impact factor: 4.356
Authors: Abdullah Al Maruf; Mikayla Fan; Paul D Arnold; Daniel J Müller; Katherine Aitchison; Chad A Bousman Journal: Can J Psychiatry Date: 2020-05-19 Impact factor: 4.356